Loading verified market, valuation, and statement data.
2. Company Fundamentals
2.3 Management
| Role |
Metric |
| Consensus Rating |
N/A |
2.4 Return
| Metric |
Value |
| Expected Return (Ann.)* |
-9.70% |
| Risk / Std Dev (Ann.)* |
23.20% |
| 1-Year Price Return* |
-11.68% |
Latest Market Data (as of 2026-08-10, Hong Kong time):
| Metric |
Value |
| Last Price |
HK$2.4 |
| 52-Week Range |
HK$2.32 – HK$3.17 |
| Observation Count |
245 trading days |
The return and risk statistics use daily adjusted closes from the retrieved one-year price series and annualise daily moments using 252 trading days. The last price is the latest regular-market price reported for the stated date. Source: Yahoo Finance market data.
DuPont Model Analysis
The DuPont model decomposes return on equity (ROE) into three operating and capital-structure drivers:
ROE = Net Margin × Asset Turnover × Equity Multiplier
The comparison uses the latest two comparable annual periods available for the issuer, with reported statement amounts shown in HK$. Revenue and net income are income-statement flows; total assets and shareholders’ equity are year-end balance-sheet figures. This is a simplified year-end-balance DuPont comparison rather than an average-balance ROE calculation.
| DuPont component |
Calculation |
FY2025 |
FY2024 |
| Revenue |
Reported revenue |
HK$494.32M |
HK$484.30M |
| Net income |
Reported net income |
HK$20.44M |
HK$14.80M |
| Total assets |
Year-end reported balance |
HK$563.30M |
HK$560.69M |
| Shareholders’ equity |
Year-end reported balance |
HK$468.27M |
HK$475.38M |
| Net margin |
Net income ÷ revenue |
4.14% |
3.06% |
| Asset turnover |
Revenue ÷ total assets |
0.8775x |
0.8638x |
| Equity multiplier |
Total assets ÷ shareholders’ equity |
1.2029x |
1.1795x |
| ROE |
Net margin × asset turnover × equity multiplier |
4.37% |
3.11% |
Source: Yahoo Finance annual statements. Values are based on the two latest comparable annual periods returned by the source; fiscal period labels use the statement period-end year.
2.5 FCFF DCF Valuation
Valuation basis: This research model follows a five-year, unlevered FCFF DCF. It starts from reported annual operating inputs, forecasts revenue and operating cash conversion under an explicit mechanical policy, discounts FCFF at WACC, applies a Gordon-growth terminal value, and bridges enterprise value to an indicative common-equity value per share. It is an analytical estimate rather than a recommendation or personalised target price.
Step 1 — Forecast Operating Profit and NOPAT
| Reported operating input |
Value |
| Revenue |
HK$494.32M |
| Prior annual revenue |
HK$484.30M |
| EBIT |
HK$32.52M |
| Tax rate |
36.41% |
| NOPAT = EBIT × (1 − tax rate) |
HK$20.68M |
| Forecast start-growth basis |
2.07% |
| Forecast policy |
latest reported annual revenue growth, bounded to -10.00% / 15.00% |
Step 2 — Calculate FCFF
| Current FCFF building block |
Value |
| NOPAT |
HK$20.68M |
| Add: depreciation & amortisation |
HK$19.93M |
| Less: capital expenditure |
-HK$6.40M |
| Less/(add): working-capital cash-flow movement |
HK$3.75M |
| Current unlevered FCFF |
HK$37.95M |
Explicit FCFF forecast
| Forecast year |
Revenue growth |
NOPAT |
D&A |
Capex |
Change in NWC |
FCFF |
Present value |
| 1 |
2.07% |
HK$21.11M |
HK$20.34M |
-HK$6.53M |
HK$3.82M |
HK$38.74M |
HK$36.74M |
| 2 |
2.18% |
HK$21.57M |
HK$20.78M |
-HK$10.20M |
HK$3.91M |
HK$36.05M |
HK$30.75M |
| 3 |
2.28% |
HK$22.06M |
HK$21.25M |
-HK$14.04M |
HK$3.99M |
HK$33.27M |
HK$25.52M |
| 4 |
2.39% |
HK$22.59M |
HK$21.76M |
-HK$18.07M |
HK$4.09M |
HK$30.37M |
HK$20.96M |
| 5 |
2.50% |
HK$23.15M |
HK$22.31M |
-HK$22.31M |
HK$4.19M |
HK$27.34M |
HK$16.97M |
Step 3 — Determine the Discount Rate (WACC)
| WACC input |
Value |
| Risk-free rate |
4.71% |
| Equity risk premium assumption |
5.50% |
| Beta |
1.20 |
| Cost of equity |
11.30% |
| Pre-tax cost of debt |
6.97% |
| WACC |
11.18% |
| WACC validation |
within standard range |
Step 4 — Estimate Terminal Value
| Terminal-value input |
Value |
| Perpetuity growth rate |
2.50% |
| Terminal value |
HK$322.75M |
| Implied terminal EV / EBITDA |
5.50x |
| Terminal value as % of enterprise value |
59.20% |
Step 5 — Discount Cash Flows to Enterprise Value
| Enterprise-value component |
Value |
| Present value of explicit FCFF |
HK$130.93M |
| Present value of terminal value |
HK$189.96M |
| Indicated enterprise value |
HK$320.89M |
| Discounting convention |
mid-year for explicit FCFF; terminal value discounted at year-end five |
Step 6 — Convert Enterprise Value to Equity Value
| Equity bridge |
Value |
| Indicated enterprise value |
HK$320.89M |
| Less: gross interest-bearing debt |
HK$4.94M |
| Add: cash and equivalents |
HK$177.93M |
| Add: affiliate investments |
HK$0.00 |
| Less: minority interests |
HK$0.00 |
| Indicated common equity value |
HK$493.88M |
Step 7 — Calculate Indicative Value Per Share
| Per-share output |
Value |
| Shares used |
122,265,585.00 |
| Share-count basis |
reported shares outstanding; option/RSU dilution data not separately available |
| Current market price |
HK$2.40 |
| DCF indicative value per share |
HK$4.04 |
| Indicative value vs. market price |
68.31% |
Model Integrity Checks
| Check |
Result |
| Perpetuity growth is below the risk-free rate |
pass |
| Perpetuity growth is below WACC |
pass |
| WACC is within the configured operating-company range |
pass |
| Terminal-year FCFF is positive |
pass |
| Terminal capex converges to D&A |
pass |
| Terminal-value concentration |
within review band |
| Implied price differs from spot by more than 30% |
review required |
2.6 Investor-Style Research Screen
| Educational screen |
Result |
| Buffett-inspired cash-quality checks |
4/4 evidenced checks |
| Lynch-inspired balance-and-growth checks |
4/4 evidenced checks |
Data lineage: Yahoo Finance public market and reported-statement data; retrieval timestamp: 2026-08-18 16:40:48.787169 UTC; latest reported fiscal period: 2025-12-31 00:00:00. Default assumptions: five-year forecast, mid-year discounting for explicit FCFF, a maximum 2.50% perpetuity-growth rate below both WACC and the risk-free rate, historical operating-ratio persistence, and capex convergence to D&A by year five. No sell-side consensus or management guidance is substituted for reported inputs. This is research and analysis only, not personalized financial advice.
2.7 Quantitative Factor Diagnostics
Model basis: Daily issuer USD excess returns are regressed in-sample using ordinary least squares on matching regional Fama–French factors. FF3 estimates market, size, and value loadings; FF5 adds profitability and investment. Coefficients are descriptive historical exposures, not predictions.
| Estimation input |
Value |
| Regional factor set |
Asia Pacific ex Japan |
| Factor-return currency |
USD |
| Issuer-return basis |
USD adjusted total return |
| Estimation window |
2025-08-20 to 2026-06-30 |
| Aligned daily observations |
210 |
| Minimum observation requirement |
120 |
| Currency conversion for HK listings |
HKD adjusted close divided by daily USD/HKD close before simple daily return calculation |
Fama–French Three-Factor and Five-Factor Results
| Diagnostic |
FF3 |
FF5 |
| Annualised alpha |
-16.11% |
-17.81% |
| Adjusted R² |
-0.00 |
-0.01 |
| Annualised residual volatility |
24.97% |
24.91% |
| Factor loading (t-statistic) |
FF3 |
FF5 |
| Market excess return (Mkt-RF) |
0.23 (1.61) |
0.28 (1.83) |
| Size (SMB) |
-0.01 (-0.05) |
0.14 (0.54) |
| Value (HML) |
0.15 (0.75) |
0.14 (0.61) |
| Profitability (RMW) |
NM |
0.10 (0.35) |
| Investment (CMA) |
NM |
0.29 (0.91) |
Definitions: Mkt-RF is the market return less the risk-free rate; SMB is small minus big; HML is high minus low book-to-market; RMW is robust minus weak profitability; CMA is conservative minus aggressive investment. Factor returns are sourced from the Kenneth R. French Data Library; issuer adjusted-return history is sourced from Yahoo Finance. For Hong Kong listings, adjusted HKD prices are converted into USD with daily USD/HKD closes before return calculation to match the USD regional factor basis. This is an in-sample historical regression; coefficients and t-statistics do not establish causation or predict future returns. This is research and analysis only, not personalized financial advice.